Genetic Technologies (ASX:GTG), known for its expertise in genomics-based testing, has introduced its most advanced risk assessment test for serious diseases – including breast and ovarian cancer. This new test builds upon the success of its Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test, marking a significant breakthrough in taking healthcare and disease precaution to the next level.
GeneType’s latest innovation is a world-first, incorporating over 200 high penetrant genes to assess the risk of hereditary diseases, including the most common cancers, cardiovascular disease, and type 2 diabetes. Unlike traditional methods that rely solely on family history (which accounts for only 5-15% of disease risk), this test identifies nearly 100% of individuals at risk, encompassing both hereditary and sporadic non-hereditary diseases.
The comprehensive nature of GeneType’s test covers approximately 70% of annual mortalities and morbidities, offering a simple non-invasive sampling method through saliva testing. With a commitment to clinically validated innovation, GeneType’s test provides unparalleled insight into an individual’s risk profile, empowering physicians to tailor interventions and treatment plans effectively, and saving millions of lives.
Some key features of the Comprehensive Risk Assessment Test include:
- Coverage of more than 200 high penetrant genes, offering a thorough evaluation of genetic predisposition to serious diseases.
- Integration of multigene panels, enhancing the detection of pathogenic genes beyond BRCA1/2, which is particularly beneficial for breast and ovarian cancer patients.
- Automatic reflex for patients without identified genetic mutations, capturing the majority at risk of serious diseases.
- Non-invasive saliva test, ensuring accessibility and accuracy for patients.
- Coverage of oncology, cardiovascular, and metabolic diseases, providing a holistic understanding of an individual’s risk profile.
With the United States healthcare market showing increasing demand for personalised medicine and preventive healthcare, Genetic Technologies’ groundbreaking test is in a strong position to meet the growing need for comprehensive genetic risk assessments.
According to Grand View Research, the genetic testing market in the United States was valued at US$7,421.08 million in 2022, reflecting the rising awareness and adoption of genetic testing for disease prevention and early intervention.
GTG has been trading at 15.5 cents.
